- 专利标题： A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A SHP2 INHIBITOR
-
申请号： US17905032申请日： 2021-02-26
-
公开(公告)号： US20230090389A1公开(公告)日： 2023-03-23
- 发明人: Diana GRAUS PORTA
- 申请人： Novartis AG
- 申请人地址： CH Basel
- 专利权人： Novartis AG
- 当前专利权人： Novartis AG
- 当前专利权人地址： CH Basel
- 国际申请： PCT/IB2021/051643 WO 20210226
- 主分类号： A61K31/506
- IPC分类号： A61K31/506 ; A61K31/497 ; A61K31/4965
摘要：
The present invention relates to a pharmaceutical combination comprising dabrafenib, an Erk-inhibitor and a SHP2 inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which MAPK pathway inhibition is beneficial, for example, in the treatment of cancers.
信息查询
IPC分类:
